Lumos Net Receivables vs Total Assets Analysis

LUMO Stock

USD 2.54 0.09 3.42%

Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Net Receivables and its Total Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Net Receivables vs Total Assets

Net Receivables vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Net Receivables account and Total Assets. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Lumos Pharma's Net Receivables and Total Assets is 0.57. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Assets in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Net Receivables and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Lumos Pharma are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Receivables i.e., Lumos Pharma's Net Receivables and Total Assets go up and down completely randomly.

Correlation Coefficient

0.57

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Total Assets

Total assets refers to the total amount of Lumos Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lumos Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 19th of May 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).

	2021	2022	2023	2024 (projected)
Interest Expense	484K	874K	1.0M	671.3K
Depreciation And Amortization	203K	49K	44K	41.8K

Interest Expense Depreciation And Amortization

Lumos Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		-0.76	0.52	0.71	0.99	0.6	0.52	-0.99	-0.02	0.56	0.99	0.59	0.07	0.99	0.57	0.12	0.0	-0.27	-0.11	0.53	0.61	0.37	0.59	1.0	-0.21	0.58
Short Long Term Debt Total	-0.76		-0.59	-0.46	-0.76	-0.09	-0.18	0.79	0.23	-0.34	-0.77	-0.08	-0.49	-0.77	-0.45	0.28	-0.28	0.2	0.23	-0.42	-0.62	-0.21	-0.06	-0.78	0.33	-0.37
Other Current Liab	0.52	-0.59		0.77	0.48	0.0	0.19	-0.5	-0.54	0.44	0.48	-0.02	0.33	0.48	0.3	-0.21	0.05	-0.34	0.14	0.6	0.71	0.39	-0.04	0.53	-0.17	0.46
Total Current Liabilities	0.71	-0.46	0.77		0.64	0.49	0.38	-0.66	-0.14	0.81	0.66	0.48	0.08	0.65	0.31	-0.01	-0.19	-0.24	0.03	0.86	0.52	0.66	0.48	0.71	-0.02	0.5
Total Stockholder Equity	0.99	-0.76	0.48	0.64		0.58	0.48	-0.99	-0.05	0.48	0.99	0.56	0.04	0.99	0.57	0.13	0.06	-0.4	-0.12	0.45	0.64	0.21	0.57	0.99	-0.17	0.57
Property Plant And Equipment Net	0.6	-0.09	0.0	0.49	0.58		0.34	-0.57	0.13	0.59	0.59	1.0	-0.49	0.59	0.12	0.47	-0.52	-0.17	-0.11	0.37	0.25	0.26	0.99	0.57	0.14	0.66
Current Deferred Revenue	0.52	-0.18	0.19	0.38	0.48	0.34		-0.46	0.38	-0.03	0.47	0.35	-0.42	0.51	0.39	0.59	-0.1	0.09	0.46	0.1	0.0	0.38	0.34	0.52	-0.11	0.15
Net Debt	-0.99	0.79	-0.5	-0.66	-0.99	-0.57	-0.46		0.09	-0.52	-1.0	-0.56	-0.13	-1.0	-0.51	-0.06	0.0	0.29	0.17	-0.47	-0.66	-0.31	-0.55	-0.99	0.21	-0.61
Retained Earnings	-0.02	0.23	-0.54	-0.14	-0.05	0.13	0.38	0.09		-0.05	-0.08	0.15	-0.39	-0.06	0.29	0.3	0.16	0.32	0.06	-0.06	-0.78	0.12	0.22	-0.03	0.11	-0.58
Accounts Payable	0.56	-0.34	0.44	0.81	0.48	0.59	-0.03	-0.52	-0.05		0.52	0.59	0.17	0.5	0.13	-0.11	-0.18	-0.09	-0.29	0.89	0.35	0.6	0.6	0.55	-0.1	0.42
Cash	0.99	-0.77	0.48	0.66	0.99	0.59	0.47	-1.0	-0.08	0.52		0.58	0.11	1.0	0.51	0.08	-0.01	-0.29	-0.16	0.46	0.65	0.31	0.57	0.99	-0.2	0.61
Non Current Assets Total	0.59	-0.08	-0.02	0.48	0.56	1.0	0.35	-0.56	0.15	0.59	0.58		-0.48	0.58	0.11	0.47	-0.54	-0.11	-0.11	0.36	0.22	0.3	0.99	0.56	0.13	0.66
Non Currrent Assets Other	0.07	-0.49	0.33	0.08	0.04	-0.49	-0.42	-0.13	-0.39	0.17	0.11	-0.48		0.09	-0.01	-0.82	0.36	0.18	-0.53	0.25	0.33	0.22	-0.5	0.1	-0.4	-0.14
Cash And Short Term Investments	0.99	-0.77	0.48	0.65	0.99	0.59	0.51	-1.0	-0.06	0.5	1.0	0.58	0.09		0.51	0.11	0.01	-0.28	-0.14	0.46	0.64	0.31	0.57	0.99	-0.21	0.6
Net Receivables	0.57	-0.45	0.3	0.31	0.57	0.12	0.39	-0.51	0.29	0.13	0.51	0.11	-0.01	0.51		0.13	0.14	-0.1	0.12	0.14	0.11	0.17	0.13	0.58	-0.17	0.05
Common Stock Total Equity	0.12	0.28	-0.21	-0.01	0.13	0.47	0.59	-0.06	0.3	-0.11	0.08	0.47	-0.82	0.11	0.13		-0.22	-0.01	0.62	-0.17	-0.15	-0.03	0.48	0.1	-0.17	0.21
Common Stock Shares Outstanding	0.0	-0.28	0.05	-0.19	0.06	-0.52	-0.1	0.0	0.16	-0.18	-0.01	-0.54	0.36	0.01	0.14	-0.22		-0.23	-0.05	-0.02	-0.1	-0.34	-0.44	0.02	-0.39	-0.57
Non Current Liabilities Total	-0.27	0.2	-0.34	-0.24	-0.4	-0.17	0.09	0.29	0.32	-0.09	-0.29	-0.11	0.18	-0.28	-0.1	-0.01	-0.23		0.02	-0.12	-0.52	0.57	-0.15	-0.28	-0.3	-0.26
Inventory	-0.11	0.23	0.14	0.03	-0.12	-0.11	0.46	0.17	0.06	-0.29	-0.16	-0.11	-0.53	-0.14	0.12	0.62	-0.05	0.02		-0.17	-0.14	0.04	-0.11	-0.11	0.0	0.01
Other Current Assets	0.53	-0.42	0.6	0.86	0.45	0.37	0.1	-0.47	-0.06	0.89	0.46	0.36	0.25	0.46	0.14	-0.17	-0.02	-0.12	-0.17		0.36	0.64	0.38	0.52	-0.15	0.27
Other Stockholder Equity	0.61	-0.62	0.71	0.52	0.64	0.25	0.0	-0.66	-0.78	0.35	0.65	0.22	0.33	0.64	0.11	-0.15	-0.1	-0.52	-0.14	0.36		0.04	0.17	0.61	-0.18	0.76
Total Liab	0.37	-0.21	0.39	0.66	0.21	0.26	0.38	-0.31	0.12	0.6	0.31	0.3	0.22	0.31	0.17	-0.03	-0.34	0.57	0.04	0.64	0.04		0.26	0.37	-0.26	0.19
Property Plant And Equipment Gross	0.59	-0.06	-0.04	0.48	0.57	0.99	0.34	-0.55	0.22	0.6	0.57	0.99	-0.5	0.57	0.13	0.48	-0.44	-0.15	-0.11	0.38	0.17	0.26		0.56	0.12	0.59
Total Current Assets	1.0	-0.78	0.53	0.71	0.99	0.57	0.52	-0.99	-0.03	0.55	0.99	0.56	0.1	0.99	0.58	0.1	0.02	-0.28	-0.11	0.52	0.61	0.37	0.56		-0.22	0.56
Short Term Debt	-0.21	0.33	-0.17	-0.02	-0.17	0.14	-0.11	0.21	0.11	-0.1	-0.2	0.13	-0.4	-0.21	-0.17	-0.17	-0.39	-0.3	0.0	-0.15	-0.18	-0.26	0.12	-0.22		0.03
Common Stock	0.58	-0.37	0.46	0.5	0.57	0.66	0.15	-0.61	-0.58	0.42	0.61	0.66	-0.14	0.6	0.05	0.21	-0.57	-0.26	0.01	0.27	0.76	0.19	0.59	0.56	0.03

Click cells to compare fundamentals

Lumos Pharma Account Relationship Matchups

Lumos Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	96.8M	129.0M	100.3M	72.3M	40.6M	38.6M
Short Long Term Debt Total	1.2M	319K	557K	233K	6.6M	6.9M
Other Current Liab	10.2M	5.9M	4.2M	6.2M	5.9M	5.9M
Total Current Liabilities	11.8M	6.5M	5.1M	6.7M	7.0M	11.8M
Total Stockholder Equity	78.9M	116.6M	89.0M	59.6M	27.3M	25.9M
Property Plant And Equipment Net	2.4M	584K	635K	283K	603K	572.9K
Net Debt	(89.3M)	(98.4M)	(94.3M)	(55.8M)	(28.5M)	(29.9M)
Retained Earnings	(334.0M)	(66.0M)	(96.4M)	(127.5M)	(161.5M)	(169.6M)
Accounts Payable	475K	244K	612K	275K	890K	845.5K
Cash	90.5M	98.7M	94.8M	56.0M	35.1M	33.3M
Non Current Assets Total	2.4M	584K	635K	283K	603K	572.9K
Non Currrent Assets Other	735K	(584K)	(635K)	(283K)	(325.5K)	(341.7K)
Cash And Short Term Investments	90.5M	98.7M	94.8M	67.4M	36.1M	34.3M
Net Receivables	824K	26.3M	128K	223K	210K	199.5K
Common Stock Total Equity	372K	373K	12K	83K	74.7K	71.0K
Common Stock Shares Outstanding	144.7K	6.8M	8.3M	8.4M	8.1M	4.1M
Liabilities And Stockholders Equity	96.8M	129.0M	100.3M	72.3M	40.6M	38.6M
Non Current Liabilities Total	6.9M	6.1M	6M	6.2M	6.3M	6.0M
Other Current Assets	3.0M	3.5M	4.7M	4.4M	3.7M	6.2M
Other Stockholder Equity	412.5M	182.5M	185.3M	187.0M	188.7M	214.3M
Total Liab	17.9M	12.5M	11.3M	12.7M	13.3M	21.4M
Property Plant And Equipment Gross	457K	584K	635K	283K	603K	572.9K
Total Current Assets	94.4M	128.4M	99.7M	72.0M	40.0M	38.0M
Accumulated Other Comprehensive Income	(6.6M)	(7.0M)	(63.5M)	(129.0M)	0.0	(9K)
Short Term Debt	1.1M	319K	352K	233K	282K	519.9K
Common Stock	373K	374K	83K	82K	81K	77.0K
Net Tangible Assets	78.9M	116.6M	89.0M	59.6M	68.5M	104.9M
Retained Earnings Total Equity	(237.5M)	(291.0M)	(334.0M)	(66.0M)	(59.4M)	(62.4M)
Capital Surpluse	389.8M	407.2M	414.0M	182.5M	209.9M	293.4M
Property Plant Equipment	1.6M	335K	635K	283K	254.7K	242.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:

How To Invest In Lumos

Details

Is Lumos Stock a good investment?

Details

What is Lumos Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Lumos Stock analysis

When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Transaction History View history of all your transactions and understand their impact on performance
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.18)

Revenue Per Share

0.252

Quarterly Revenue Growth

0.613

Return On Assets

(0.41)

Return On Equity

(0.78)

The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lumos Net Receivables vs Total Assets Analysis

Net Receivables vs Total Assets

Net Receivables vs Total Assets Correlation Analysis

Correlation Coefficient

Net Receivables

Total Assets

Lumos Pharma fundamental ratios Correlations

Lumos Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lumos Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lumos Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Common Stock Total Equity	- 0.82	Non Currrent Assets Other